The wait to see cardiovascular outcomes data on Amgen Inc.’s Repatha (evolocumab) and Sanofi/Regeneron Pharmaceuticals Inc.’s Praluent (alirocumab) just got even more interesting after Pfizer Inc. announced Nov. 1 that it is discontinuing development of its late-stage PCSK9 inhibitor bococizumab due to the clinical profile.
The news – coinciding with the company’s third quarter sales and earnings report – surprised investors because PCSK9 is a...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
